Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CANF.TA
- Price
- 2.00
- Stock movement up
- +0.20 (11.11%)
- Company name
- Can Fite Biopharma Ltd
- Exchange
- (TA ,
- Currency
- ILA )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.66B
- Ent value
- 3.66B
- Price/Sales
- 4923.10
- Price/Book
- 585.91
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -49.02%
- 1 year return
- -33.33%
- 3 year return
- -43.52%
- 5 year return
- -33.26%
- 10 year return
- -44.83%
Last updated: 2025-04-15
DIVIDENDS
CANF.TA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4923.10 |
| Price to Book | 585.91 |
| EV to Sales | 4922.38 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.83B |
| EPS (TTM) | -0.01 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 743.00K |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -8.20M |
| Net income (TTM) | -7.63M |
| EPS (TTM) | -0.01 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | -1102.96% |
| Profit margin (TTM) | -1027.46% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.28M |
| Net receivables | 0.00 |
| Total current assets | 9.91M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 344.00K |
| Total assets | 9.99M |
| Accounts payable | 427.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 2.02M |
| Total liabilities | 3.75M |
| Shareholder's equity | 6.24M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -122.28% |
| Return on Assets | -76.42% |
| Return on Invested Capital | -122.28% |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.90 |
| Daily high | 2.00 |
| Daily low | 1.80 |
| Daily Volume | 3.94M |
| All-time high | 102500.00 |
| 1y analyst estimate | 6.00 |
| Beta | 0.57 |
| EPS (TTM) | -0.01 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CANF.TA | S&P500 | |
| Current price drop from All-time high | -100.00% | -12.04% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 19 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -81.75% | -11.07% |
| Avg time to new high | 1596 days | 12 days |
| Max time to new high | 4706 days | 1805 days |
COMPANY DETAILS
Marketcap
3.66B
Marketcap category
Mid-cap
Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Employees
8
Website
Investor relations
-
SEC filings
CEO
Country
Israel
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found